Background and objective: Idiopathic pulmonary fibrosis (IPF) is a progressive disease with poor prognosis and variable clinical course. Although matrix metalloproteinase-7 (MMP-7) is emerging as an important IPF biomarker, reproducibility across studies is unclear. We aimed to determine whether a previously reported prognostic threshold for MMP-7 was predictive of mortality in an independent cohort of IPF patients. Methods: MMP-7 concentrations obtained from heparinized plasma samples were determined by ELISA in 97 patients with IPF and 41 healthy controls. The association of the previously published heparin plasma MMP-7 threshold of 12.1 ng/mL with all-cause mortality or transplant-free survival (TFS) was determined, either as an independent biomarker or as part of the modified personal clinical and molecular mortality index (m-PCMI). Results: MMP-7 plasma concentrations were significantly higher in IPF patients compared to healthy controls (14.40 AE 6.55 ng/mL vs 6.03 AE 2.51 ng/mL, P < 0.001). The plasma MMP-7 threshold of 12.1 ng/mL was significantly associated with both all-cause mortality and TFS (unadjusted Cox proportional hazard ratio (HR) = 25.85 and 15.49, 95% CI: 10.91-61.23 and 5.41-44.34, respectively, P < 0.001). MMP-7 concentrations, split by 12.1 ng/mL, were significantly (P < 0.05) predictive of mortality and TFS after adjusting for age, gender, smoking and baseline pulmonary function parameters, in a multivariate Cox proportional hazards model. MMP-7 concentrations were negatively correlated with diffusing lung capacity of carbon monoxide (DL CO ) (r = −0.21, P = 0.02), and positively with a mortality risk scoring system (GAP) that combines age, gender, forced vital capacity (FVC) and DL CO (r = 0.32, P = 0.001). Conclusion: This study confirms that MMP-7 concentrations could be used to accurately predict outcomes across cohorts and centres, when similar collection protocols are applied.
INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease that is often fatal within 3-5 years after initial diagnosis. 1 Despite extensive research efforts, its aetiology in humans still remains largely unknown, and no curative drug therapies are available. [2] [3] [4] The clinical course and rate of disease progression are heterogeneous and relatively unpredictable. [5] [6] [7] Previous studies aimed to identify clinical and physiological parameters that predict mortality and defined multidimensional indices to estimate the risk of death in patients with IPF. 3, [8] [9] [10] However, none of these clinical markers predicts disease behaviour accurately enough to guide patient management decisions such as priority for lung transplantation,
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The generalizability of the prognostic value of matrix metalloproteinase-7 (MMP-7) in idiopathic pulmonary fibrosis (IPF) has been questioned. We reproduced prognostic accuracy of a previously published threshold of MMP-7 in an independent cohort of patients with IPF based on similarities in collection matrices. MMP-7 predictive value is robust when heparin plasma is used as collection matrix.
timely referral to palliative care or other therapeutic decisions. 11 Although fibrosis in IPF is limited to the lung, evidence suggests that proteins and genes in peripheral blood differentiate IPF patients from healthy controls and may predict mortality. 12 Of these, matrix metalloproteinase-7 (MMP-7) has emerged as an important biomarker, reproducibly indicative of disease presence, severity and prognosis. [13] [14] [15] Plasma MMP-7 plasma concentrations in IPF are linked with two singlenucleotide polymorphisms in the gene's promoter region, suggesting potential genetic basis for MMP-7 upregulation. 16 We have demonstrated that plasma MMP-7 concentration predicted mortality in two cohorts of patients with IPF (n = 241) and developed a personal clinical and molecular mortality index (PCMI) that accurately distinguished high-from low-risk mortality groups. 13 More recently, plasma MMP-7 concentration was reported as an independent predictor of survival in a prediction model containing clinical indices and MUC5B genotype, in two cohorts with 586 IPF patients. 17 These findings were replicated by Song et al. in a moderately sized cohort of patients with IPF (n = 118). 15 Finally, plasma MMP-7 has been proposed as a univariate predictor of early interstitial lung disease abnormalities in first-degree relatives of patients with familial interstitial pneumonia. 18 Despite these impressive data, the implementation of MMP-7 in clinical decisionmaking has significantly lagged. 19 The most important reason for this is lack of standardization. Sample collection protocols and matrices differed across studies, as did individual study derived prognostic cut-off points, thus justifiably preventing generalization of results.
In this study, we aimed to determine whether a prognostic threshold identified in a previous study would be significantly predictive of outcome in a completely independent cohort. To this end, we decided not to derive MMP-7 cut-off thresholds based on our own cohort. Instead, given similarities in sample management procedures and collection matrices, we chose to test whether the plasma MMP-7 threshold identified by Song et al. 15 was an accurate prognostic marker in our cohort.
METHODS

Patients and plasma samples
Source data included samples and clinical information from 97 patients with IPF from the Yale Center of Excellence for Interstitial Lung Disease and 41 age and sex matched healthy donors recruited from the local New Haven Community. IPF diagnosis was based on guidelines of the American Thoracic Society and European Respiratory Society. 2 All patients and healthy donors provided written informed consent and a protocol incorporating biomarker-studies was approved by the Institutional Review Board (IRB), Yale School of Medicine (HIC#0706002766).
MMP-7 quantification
This was a prospective observational cohort study. Yale patient samples were obtained at routine visits from treatment-naïve subjects that were not currently enrolled in clinical studies. Blood was collected in heparin tubes using a routine procedure and was immediately (within 10 min after blood collection) centrifuged at 4 C, 1200 g for 10 min. Plasma was aliquoted and frozen at −80 C until analysis by ELISA for MMP-7. The ELISA kit chosen (R&D Systems, Inc., MN, USA) has been widely used 14, 20, 21 and has a reported sensitivity of: 0.094 ng/mL, an assay range: 0.2-10 ng/mL and minimal cross-reactivity (0.5%) (R&D Systems, Inc., MN, USA). The resultant trend line produced an r 2 of at least 0.99 and coefficient variability (CV) for intra-assay variations was 4.79% indicating significant reproducibility among duplicates. Heparin plasma samples were diluted 1:5. All assays were performed in duplicate and the mean values were reported.
Statistical analysis
Data were statistically analysed using Med. Calc. version 14. Comparisons of plasma MMP-7 concentrations in IPF patients and healthy donors were performed using Mann Whitney U-test or unpaired two-tailed t-test. For baseline characteristics, comparisons between IPF patients and controls or between IPF subgroups (high and low plasma MMP-7 concentrations) were performed using the Fisher's exact test. For age, pulmonary function tests, GAP and modified PCMI (m-PCMI), unpaired, two-tailed, Student's t-test was used. Spearman correlations were used to assess associations between MMP-7 and functional parameters. In analyses of all-cause mortality and transplant-free survival (TFS), patients were followed up from enrolment to death or censored at either the end of follow-up or time of lung transplantation or ≥10% drop in forced vital capacity (FVC) % predicted. For mortality, patients were censored at transplant and deaths were considered events. For TFS, transplants and deaths were both counted as events. Derivation of an m-PCMI, a risk prediction rule published by us, 13 was based on the following formula:
, where DL CO is the diffusing lung capacity of carbon monoxide and the indicator function I() is unity (one) if and only if the condition inside the parentheses is true. Associations of the previously published plasma MMP-7 threshold of 12.1 ng/ mL 15 with all-cause mortality, TFS or disease progression as measured by drop of ≥10% in FVC% predicted were evaluated using Kaplan-Meier approach. The multivariate Cox regression hazard ratio (HR) models were used to investigate the associations between MMP-7 cut-off point of 12.1 ng/mL and mortality or TFS or drop of ≥10% in FVC% predicted. The covariates considered included age, gender, smoking, FVC% predicted and DL CO % predicted.
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RESULTS
Patients and healthy controls demographic data
Baseline characteristics of patients and healthy controls are presented in Table 1 . This study population included 97 patients with IPF and 41 healthy controls matched for age and gender. Patients with IPF were predominantly white (87.6%), male (78.4%) and former smokers (65.9%). Baseline mean FVC% predicted was 75.9 and DL CO % predicted was 51. Diagnosis was based on surgical lung biopsy in 23.7% of our patients. The median follow-up time was 563 days and 7% of our patients received a lung transplant. The rate of death in the first and second year of follow-up was 11% and 14%, respectively. As expected, healthy controls had a significantly higher percentage of never-smokers and lower percentage of ex-smokers compared to patients with IPF (85.4% vs 27.8% and 14.6% vs 65.9%, P < 0.001).
Plasma MMP-7 concentrations are higher in patients with IPF compared to healthy controls
Mean plasma MMP-7 concentrations were significantly elevated in patients with IPF compared to controls (14.40 AE 6.55 vs 6.03 AE 2.51, P < 0.001) ( Table 2 , Fig. 1A ). Receiver operating characteristic (ROC) curve analysis (Fig. 1B) revealed that the cut-off value of 8.18 ng/mL could distinguish patients with IPF from controls with a sensitivity of 87.63% and specificity of 82.93% (area under the curve (AUC): 0.92, P < 0.001).
Plasma MMP-7 threshold of 12.1 ng/mL and m-PCMI predict mortality
Previously published 15 plasma MMP-7 threshold of 12.1 ng/mL was also incorporated into a multidimensional prediction rule, denominated PCMI. Given that the cut-off value of plasma MMP-7 in the current cohort was different (12.1 ng/mL vs 4.3 ng/mL) than the one published by Richards et al., 13 a new version of PCMI was generated and called m-PCMI. Plasma MMP-7 cut-off P-values were calculated using the unpaired, two-tailed Student's t-test or Mann Whitney U-test.
† Lower limit of detection (0.16 ng/mL). CI, confidence interval; IPF, idiopathic pulmonary fibrosis; MMP-7, matrix metalloproteinase-7; SD, standard deviation. Figure 2 . ROC curve analysis revealed that plasma MMP-7 threshold of 12.1 ng/mL exhibited a sensitivity of 95.2% and 92.9%, and specificity of 63.2% and 57.8% for predicting all-cause mortality and TFS, respectively. (Tables S1,S2 , Supplementary Information). The associations between DL CO and all-cause mortality as well as TFS were significant in the multivariate model (P = 0.006 and 0.03, respectively). With regard to GAP score, only when used as a univariate predictor, the association with allcause mortality and TFS was significant (P = 0.01 and 0.02, respectively). IPF patients with higher plasma MMP-7 levels (≥12.1 ng/mL) exhibited more severe disease as assessed by almost significant reductions in DL CO (44.19 AE 14.35 vs 50.58 AE 18.65, P = 0.06), as well as subsequent increases in GAP (median: 5 vs 4, P = 0.02) and m-PCMI (444.19 AE 75.20 vs 285.44 AE 93.86, P < 0.001) indices, compared to patients with lower plasma MMP-7 levels (<12.1 ng/ mL). All-cause mortality was 41% (20 deaths) in the high MMP-7 group versus 2% (1 death) in the low MMP-7 group (Table 3) .
Plasma MMP-7 concentration correlates with functional and clinical predictors of mortality
Plasma MMP-7 concentration, used as a continuous variable, correlated with disease severity across multiple measures of patient functional status. Baseline plasma MMP-7 concentration was negatively correlated with DL CO (r = −0.21, 95% CI: −0.42 to −0.04, P = 0.02) (Fig. 3A) but not with FVC% predicted (r = −0.16, 95% CI: −0.35 to 0.05, P = 0.12) (Fig. 3B) . Plasma MMP-7 concentrations also showed a strong positive association with the GAP score (r = 0.32, 95% CI: 0.13-0.49, P = 0.001) (Fig. 3C) . Baseline plasma MMP-7 concentration (split by the cut-off value of 12.1 ng/mL) did not correlate with disease progression as measured by absolute or relative% drop in FVC both at univariate (unadjusted HR = 1.8, 95% CI: 0.8-4.2, P = 0.2 and HR = 1.3, 95% CI: 0.6-2.6, P = 0.5) and multivariate Cox regression HR analyses (HR = 2.2, 95% CI: 0.8-5.5, P = 0.1 and HR = 1.2, 95% CI: 0.6-2.5, P = 0.6) adjusted for age, gender, smoking and DL CO , respectively.
DISCUSSION
In this study, we validated the prognostic accuracy of a previously reported threshold (12.1 ng/mL) 15 of plasma MMP-7 concentrations in a moderately sized cohort of patients with IPF (n = 97). We first showed that plasma MMP-7 concentrations were significantly elevated in patients with IPF compared to controls. We then used the 12.1 ng/mL threshold of plasma MMP-7 as a dichotomous variable and confirmed previously published associations 13, 14 with all-cause mortality and TFS. In addition, we incorporated the MMP-7 cut-off value of 12.1 ng/mL into a multidimensional risk prediction rule and generated an m-PCMI that displayed sufficient prognostic power. Finally, plasma MMP-7 concentrations exhibited strong correlations with functional and clinical predictors of mortality.
IPF presents a major challenge in clinical research due to its unpredictable clinical course and the lack of easily reproducible surrogate markers for patient relevant outcomes. 22 In recent years, there has been significant progress in identifying proteins, 13, [23] [24] [25] gene variants 17, 26 and changes in blood gene expression 12 that distinguish IPF patients with distinct clinical P-values were calculated using the Fisher's exact test except for age, pulmonary function tests, GAP and m-PCMI where an unpaired, two-tailed, Student's t-test was used.
† Two patients were excluded from analysis due to missing functional parameters. DL CO , diffusing lung capacity of carbon monoxide; FVC, forced vital capacity; IQR, interquartile range; MMP-7, matrix metalloproteinase-7; m-PCMI, modified personal clinical and molecular mortality index; NA, not applicable; SD, standard deviation.
outcomes. Despite these efforts, currently available molecular biomarkers present with appreciable limitations that hamper their widespread clinical applicability. 19, 27 MMP-7, a WNT/β-catenin target gene, is a matrix metalloprotease overexpressed in hyperplastic epithelial cells in IPF. 28, 29 MMP-7-deficient mice are relatively protected from bleomycin-induced lung fibrosis. 28, 30 Overexpression of MMP-7 by epithelial cells may be profibrotic through several mechanisms including cleavage and activation of numerous profibrotic substrates, such as osteopontin 31 and TNF-α. 30, 32 An association of elevated concentrations of MMP-7 with increased mortality in patients with IPF and other chronic lung diseases has been found repeatedly. [33] [34] [35] [36] However, the potential implementation of MMP-7 as a prognostic biomarker in clinical practice has been delayed by the lack of reproducible and uniform cut-off thresholds across multiple studies. Different collection matrices 37, 38 may account for these highly variable and conflicting thresholds. The studies by Richards et al., 13 Rosas et al. 14 and Peljto et al. 17 used EDTA-containing tubes, whereas Song et al. 15 used heparin plasma samples. None of the studies tried to validate previously derived thresholds. Thus, we decided to test the ability of a threshold derived in a Korean cohort of patients with IPF to segregate patients with significantly different outcomes in our cohort. The choice of the MMP-7 threshold was based on similar collection matrices (heparin plasma), collection procedures (single centre) and methods of analysis (ELISA) as well as study design. Our cohort was slightly older (62.8 vs 70.0) and had more advanced disease as assessed by lower baseline mean DL CO concentrations (65 vs 51) than the Ulsan University cohort. Consistent with that, the mean plasma MMP-7 concentrations of the Ulsan University cohort 15 were slightly lower than ours (13.7 vs 14.4 ng/ mL). Impressively, the threshold derived at Ulsan University was significantly associated both with all-cause mortality and TFS (unadjusted HR = 25.85 and 15.49, respectively) and exhibited higher sensitivity and specificity in predicting all-cause mortality compared to those reported by Song et al. (95% vs 71% and 63.2% vs 54%, respectively). These findings confirmed the original observations that IPF patients can be segregated based on their blood MMP-7 concentrations compared to those with low mortality and those with high mortality. Importantly our results established, for the first time in IPF, that a threshold derived in one centre, can accurately predict survival in a completely separate cohort.
In a previous study, we derived a multidimensional risk prediction rule (PCMI) that combined demographic, functional and molecular components and was highly predictive of mortality in two independent cohorts of patients with IPF.
13 m-PCMI, generated by inserting the University of Ulsan derived MMP-7 cut-off threshold of 12.1 ng/mL to the original PCMI equation, was significantly predictive of mortality. These results replicate and validate the predictive value of the PCMI as a combined clinical and molecular predictor of mortality in IPF.
This study had several limitations. First, this was a moderately sized and relatively underpowered study. Therefore, the high HR reported for this small population is likely to overestimate the risk associated with elevated MMP-7 concentrations in the general IPF population. Second, the follow-up period was relatively short (approximately 1.5 years) compared to those reported in other similar studies; 13 however, it was sufficient to reproduce the prognostic significance of heparin plasma MMP-7 in IPF patients. Finally, while we observed significantly increased plasma MMP-7 concentrations in IPF patients, this study was not designed to test whether plasma MMP-7 concentrations could be used to reliably differentiate patients with IPF from controls or other diseases. Several other studies 14, 33, 36, 39, 40 have suggested that MMP-7, most commonly in combination with other molecular biomarkers, may distinguish IPF from other chronic lung diseases but they remain limited in size and need further validation.
In summary, to the best of our knowledge, this the first study that reproduces prognostic accuracy of a previously published threshold of an IPF peripheral blood biomarker in an entirely different cohort of patients. Our results demonstrate that, when similar sample management procedures and collection matrices (heparin plasma) are applied, baseline plasma MMP-7 concentrations exhibit remarkable and highly reproducible prognostic value across different cohorts. To better determine the specific role of MMP-7 in the management of patients with IPF, additional studies that include assessment of changes in plasma MMP-7 concentration over time and disease progression, as well as response to therapy will be required.
